A DNA methylation-based test for esophageal cancer detection

Area of Science:

• Oncology
• Epigenetics
• Molecular Diagnostics

Background:

• Esophageal cancer (ECa) is a leading cause of cancer death, often diagnosed at advanced stages with poor prognosis.
• Early detection biomarkers are crucial for improving patient management, treatment efficacy, and survival outcomes.
• DNA methylation represents a promising avenue for developing epigenetic biomarkers for ECa.

Purpose of the Study:

• To identify and validate DNA methylation-based biomarkers for early detection of esophageal cancer.
• To assess the potential of these biomarkers in predicting response to therapy.
• To differentiate between various subtypes of esophageal cancer and normal tissues.

Main Methods:

• Quantitative methylation-specific PCR was employed to analyze promoter methylation levels.
• Tissues analyzed included treatment-naïve ECa, post-neoadjuvant treatment ECa, and normal esophagus samples.
• Specific genes targeted for methylation analysis were COL14A1, GPX3, and ZNF569.

Main Results:

• ZNF569 methylation levels significantly distinguished ECa from normal tissues (p < 0.001).
• COL14A1 and GPX3 methylation levels differentiated adenocarcinomas and squamous cell carcinomas, respectively, from normal tissues (p = 0.002 and p = 0.009).
• Combined methylation markers achieved high accuracy in identifying specific ECa subtypes (e.g., 82.29% for adenocarcinomas).

Conclusions:

• A panel of methylated genes demonstrates significant biomarker potential for esophageal cancer.
• These DNA methylation markers may facilitate early ECa detection.
• The identified biomarkers could potentially aid in the detection of minimal residual disease post-therapy.